Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing

被引:25
|
作者
Kuenstner, Axel [1 ,2 ,3 ]
Witte, Hanno M. [4 ,5 ]
Riedl, Joerg [4 ,6 ]
Bernard, Veronica [6 ]
Stoelting, Stephanie [6 ]
Merz, Hartmut [6 ]
Olschewski, Vito [4 ]
Peter, Wolfgang [7 ,8 ,9 ]
Ketzer, Julius [10 ]
Busch, Yannik [7 ]
Trojok, Peter [7 ]
von Bubnoff, Nikolas [3 ,4 ]
Busch, Hauke [1 ,2 ,3 ]
Feller, Alfred C. [6 ]
Gebauer, Niklas [3 ,4 ]
机构
[1] Univ Lubeck, Med Syst Biol Grp, Lubeck, Germany
[2] Univ Lubeck, Inst Cardiogenet, Lubeck, Germany
[3] Univ Hosp Schleswig Holstein, Univ Canc Ctr Schleswig Holstein, Campus Lubeck, Lubeck, Germany
[4] Univ Hosp Schleswig Holstein, Dept Hematol & Oncol, Campus Lubeck, Lubeck, Germany
[5] Fed Armed Forces Hosp Ulm, Dept Hematol & Oncol, Ulm, Germany
[6] Reference Ctr Lymph Node Pathol & Hematopathol, Hamatopathol Lubeck, Lubeck, Germany
[7] Stefan Morsch Fdn, HLA Typing Lab, Birkenfeld, Germany
[8] Univ Cologne, Fac Med, Cologne, Germany
[9] Univ Hosp Cologne, Inst Transfus Med, Cologne, Germany
[10] Univ Hosp Schleswig Holstein, Dept Pediat, Campus Lubeck, Lubeck, Germany
关键词
BURKITT-LYMPHOMA; SURVIVAL; CANCER; EXPRESSION; SIGNATURES; PROGNOSIS; DISTINCT; DLBCL; TOOL;
D O I
10.3324/haematol.2021.279631
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
High-grade B-cell lymphoma accompanied with double/triple-hit MYC and BCL2 and/or BCL6 rearrangements (HGBLDH/TH) poses a cytogenetically-defined provisional entity among aggressive B-cell lymphomas that is traditionally associated with unfavorable prognosis. In order to better understand the mutational and molecular landscape of HGBLDH/TH we here performed whole-exome sequencing and deep panel next-generation sequencing of 47 clinically annotated cases. Oncogenic drivers, mutational signatures and perturbed pathways were compared with data from follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). We find an accumulation of oncogenic mutations in NOTCH, IL6/JAK/STAT and NF.B signaling pathways and delineate the mutational relationship within the continuum between FL/DLBCL, HGBL-DH/TH and BL. Further, we provide evidence of a molecular divergence between BCL2 and BCL6 rearranged HGBL-DH. Beyond a significant congruency with the C3/EZB DLBCL cluster in BCL2 rearranged cases on an exome-wide level, we observe an enrichment of the SBS6 mutation signature in BCL6 rearranged cases. Differential gene set enrichment and subsequent network propagation analysis according to cytogenetically defined subgroups revealed an impairment of TP53 and MYC pathway signaling in BCL2 rearranged cases, whereas BCL6 rearranged cases lacked this enrichment, but instead showed impairment of E2F targets. Intriguingly, HGBL-TH displayed intermediate mutational features considering all three aspects. This study elucidates a recurrent pattern of mutational events driving FL into MYC-driven BCL2-rearranged HGBL, unveiling the mutational pathogenesis of this provisional entity. Through this refinement of the molecular taxonomy for aggressive, germinal center-derived B-cell lymphomas, this calls into question the current World Health Organization classification system, especially regarding the status of MYC/BCL6rearranged HGBL.
引用
收藏
页码:1850 / 1863
页数:14
相关论文
共 50 条
  • [31] Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
    Li, Weiping
    Gupta, Shiv K.
    Han, Weiguo
    Kundson, Ryan A.
    Nelson, Sara
    Knutson, Darlene
    Greipp, Patricia T.
    Elsawa, Sherine F.
    Sotomayor, Eduardo M.
    Gupta, Mamta
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [32] BCL2 and BCL6 atypical/unbalanced gene rearrangements in diffuse large B-cell lymphoma are indicators of an aggressive clinical course
    Tourneret, Alicia
    Alame, Melissa
    Rigau, Valerie
    Bauchet, Luc
    Fabbro, Michel
    De Oliveira, Laura
    Cacheux, Valere
    Costes, Valerie
    Lacheretz-Szablewski, Vanessa
    JOURNAL OF CLINICAL PATHOLOGY, 2021, 74 (10) : 650 - 656
  • [33] Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas
    Willenbacher, Ella
    Willenbacher, Wolfgang
    Weger, Roman
    Dominik, Wolf
    Manzl, Claudia
    Brunner, Andrea
    ANNALS OF HEMATOLOGY, 2020, 99 (09) : 2125 - 2132
  • [34] Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases
    Pina-Oviedo, Sergio
    Bellamy, William T.
    Gokden, Murat
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2020, 48
  • [35] Using Gene Expression Profiling to Move Beyond MYC/BCL2 Rearrangements in High-Grade Lymphoma
    Chan, Wing C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (03) : 175 - +
  • [36] CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature-expressing DLBCL
    Alduaij, Waleed
    Jiang, Aixiang
    Villa, Diego
    Collinge, Brett
    Ben-Neriah, Susana
    Boyle, Merrill
    Meissner, Barbara
    Hilton, Laura K.
    Farinha, Pedro
    Slack, Graham W.
    Craig, Jeffrey W.
    Gerrie, Alina S.
    Freeman, Ciara L.
    Mungall, Andrew J.
    Steidl, Christian
    Sehn, Laurie H.
    Scott, David W.
    Savage, Kerry J.
    BLOOD, 2025, 145 (06) : 590 - 596
  • [37] Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies
    Dheur, Marie-Sophie
    Poirel, Helene A.
    Ameye, Genevieve
    Tilman, Gaelle
    Saussoy, Pascale
    Defour, Jean-Philippe
    Camboni, Alessandra
    Van den Neste, Eric
    Coulie, Pierre G.
    van Baren, Nicolas
    LEUKEMIA & LYMPHOMA, 2019, 60 (04) : 1043 - 1052
  • [38] Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma
    Dupont, Thibault
    Yang, ShaoNing
    Patel, Jayeshkumar
    Hatzi, Katerina
    Malik, Alka
    Tam, Wayne
    Martin, Peter
    Leonard, John
    Melnick, Ari
    Cerchietti, Leandro
    ONCOTARGET, 2016, 7 (03) : 3510 - 3522
  • [39] Complex Karyotype in a Pediatric Patient with Double-Hit BCL6 High-Grade B-Cell Lymphoma
    Quatrin, Mariana
    Romano, Silvina
    Cabaleiro, Laura
    Pasti, Claudia
    Iarossi, Belen
    Perez, Paula
    Altamirano, Eugenia Margarita
    Schuttenberg, Virginia
    Laudicina, Alejandro
    Montenegro, Mauro Garcia
    Slavutsky, Irma
    PEDIATRIC BLOOD & CANCER, 2025, 72 (03)
  • [40] Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
    Weiping Li
    Shiv K. Gupta
    Weiguo Han
    Ryan A. Kundson
    Sara Nelson
    Darlene Knutson
    Patricia T. Greipp
    Sherine F. Elsawa
    Eduardo M. Sotomayor
    Mamta Gupta
    Journal of Hematology & Oncology, 12